(1 - 13 von 22
)
Sanofi Completes Principia Acquisition | CHEManager
www.chemanager-online.com
Along with diseases of the nervous system, Principia hopes to develop an entire portfolio of similar drugs that could target different organ systems in patients suffering from “immune-mediated” diseases, CEO Martin Babler said recently.
Sanofi to acquire Principia Biopharma News ...
m.ariva.de
Aug 17, · The benefit of developing several BTK inhibitors will allow us to target specific organ systems for optimal patient benefit. The merger will provide global resources to get these novel therapies to patients faster,” said Martin Babler, President and CEO at Principia Biopharma.
French group Sanofi to buy US firm Principia Biopharma for $ www.wionews.com › world › french-group-sanofi-t...
www.wionews.com
· "The merger will provide global resources to get these novel therapies to patients faster," said Martin Babler, president and chief ...
Principia Biopharma Agrees to Sell to Sanofi for Approximately ...www.cooley.com › news › coverage ›
www.cooley.com
· ... treatment for patients with immune-mediated diseases,” Martin Babler, president and CEO at Principia Biopharma, said in a news release.
sortiert nach Relevanz / Datum